Literature DB >> 1562726

Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

R Wesselschmidt1, K Likert, T Girard, T C Wun, G J Broze.   

Abstract

Tissue factor pathway inhibitor (TFPI) is a multivalent Kunitz-type protease inhibitor that binds to and inactivates factor Xa directly, and in a factor Xa-dependent fashion inhibits the factor VIIa/tissue factor catalytic complex. TFPI is a slow, tight-binding, competitive, and reversible inhibitor of factor Xa, in which the formation of an initial encounter complex between TFPI and factor Xa is followed by slow isomerization to a final, tightened complex. Wild-type recombinant TFPI (rTFPI), expressed in mouse C127 cells, separates into two forms on heparin-agarose chromatography that elute at 0.3 mol/L and 0.6 mol/L NaCl. Western blot analysis shows that both forms contain the N-terminus of full-length TFPI, but only rTFPI(0.6) is recognized by an antibody directed against the C-terminus. rTFPI(0.3) and rTFPI(0.6) inhibit factor Xa with 1:1 stoichiometry and inhibit factor VIIa/tissue factor equally in an endpoint-type assay. However, rTFPI(0.6) is a more potent inhibitor than rTFPI(0.3) of coagulation in normal plasma induced by either factor Xa or tissue factor. The initial inhibition of factor Xa (less than 5 seconds) produced by rTFPI(0.6) is several-fold greater than that produced by rTFPI(0.3), presumably reflecting a lower Ki of the immediate encounter complex between factor Xa and TFPI. The differential effect of these forms of TFPI on tissue factor-induced coagulation in normal plasma appears to be directly related to their ability to inhibit factor Xa. To confirm the role of the C-terminal region of TFPI in optimal factor Xa inhibition, a carboxy-terminal mutant of rTFPI, which is truncated after leucine 252 and thus lacks the basic sequence K T K R K R K K Q R V K (residues 254-265), was expressed in C127 cells. This form of rTFPI elutes from heparin-agarose at 0.28 mol/L NaCl and inhibits factor Xa at a rate that is slower than rTFPI(0.3). The Ki(final)s for factor Xa inhibition by rTFPI(0.6), rTFPI(0.3), and rTFPI1-252 are 3.1 +/- 0.6, 19.6 +/- 0.8, and 19.6 +/- 3.0 pmol/L, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1562726

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

2.  C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules.

Authors:  Praveen Papareddy; Martina Kalle; Gopinath Kasetty; Matthias Mörgelin; Victoria Rydengård; Barbara Albiger; Katarina Lundqvist; Martin Malmsten; Artur Schmidtchen
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

3.  The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Authors:  M Ndonwi; T J Girard; G J Broze
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

4.  Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo.

Authors:  Dongying Ma; Daniella M Mizurini; Teresa C F Assumpção; Yuan Li; Yanwei Qi; Michail Kotsyfakis; José M C Ribeiro; Robson Q Monteiro; Ivo M B Francischetti
Journal:  Blood       Date:  2013-10-24       Impact factor: 22.113

5.  The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

Authors:  I Warshawsky; G Bu; A Mast; J E Saffitz; G J Broze; A L Schwartz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

7.  Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.

Authors:  Shuchong Pan; Thomas A White; Tyra A Witt; Anca Chiriac; Cheri S Mueske; Robert D Simari
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

8.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

Authors:  Tilman M Hackeng; Kristin M Seré; Guido Tans; Jan Rosing
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

9.  Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor.

Authors:  C A Sprecher; W Kisiel; S Mathewes; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

10.  Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Authors:  Michiel J B Kemme; Jacobus Burggraaf; Rik C Schoemaker; Cornelis Kluft; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.